Press Releases

Press Releases

August 8, 2018

CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma

July 26, 2018

CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors

April 23, 2018

CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy

April 17, 2018

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018

March 22, 2018

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of Crown Bio CTLA-4 Antibody

March 14, 2018

CBT Pharmaceuticals to Present at Upcoming Investor Conferences

October 30, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics

September 28, 2017

CBT Pharmaceuticals Announces First U.S. Patient Dosed in Phase 1 Clinical Trial of c-Met inhibitor, CBT-101, for Advanced Solid Tumors with c-Met Dysregulation

August 28, 2017

CBT Pharmaceuticals Appoints Nationally Recognized Leaders in Oncology to Newly Established Scientific Advisory Board

April 4, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017

Subscribe